Electromed (ELMD) 15th Annual LD Micro Invitational 2025 summary

Company overview and market position

• Focuses on airway clearance medical devices, headquartered in Minnesota, with all manufacturing and most sourcing local, minimizing tariff exposure.

• Holds a leadership position in the expanding airway clearance market, specifically targeting bronchiectasis with high-frequency chest wall oscillation (HFCWO) technology.

• Generates about $60 million in annual revenue, is profitable, has no debt, and maintains $14 million in cash.

• Recently completed and announced $5 million stock repurchases.

• Operates primarily in the home care market, with 94% of revenue from home-based sales and a smaller hospital business.

Market opportunity and growth strategy

• Bronchiectasis is underdiagnosed and underprescribed, with a U.S. market of 824,000 diagnosed patients and a $2.3 billion addressable value among those seen by pulmonologists.

• An additional 4.1 million COPD patients may have undiagnosed bronchiectasis, representing significant untapped potential.

• Growth strategy centers on expanding the sales force, direct-to-consumer marketing, and provider education to increase awareness and prescriptions.

• Consistent double-digit organic growth is targeted, with operating leverage improvements over the past 18 months.

• Annual addition of 4-5 sales reps, with buybacks prioritized in the absence of M&A or other investments.

Product innovation and competitive advantages

• Clearway device, introduced two years ago, features a unique one-hose design, lightweight vest, and Velcro enclosures for ease of use, especially for elderly and arthritic patients.

• Only HFCWO provider with these ergonomic features, driving compliance and patient satisfaction.

• Direct billing to payers increases profitability by avoiding margin sharing.

• Lifetime warranty on products, with replacement parts provided as needed, enhances value for patients and payers.